This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Sesen Bio Past Earnings Performance
Past criteria checks 0/6
Key information
18.7%
Earnings growth rate
38.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 75.1% |
| Return on equity | -12.6% |
| Net Margin | -49.7% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Sesen Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 40 | -20 | 40 | 37 |
| 30 Sep 22 | 60 | -3 | 41 | 19 |
| 30 Jun 22 | 20 | 48 | 42 | 0 |
| 31 Mar 22 | 22 | 54 | 33 | 0 |
| 31 Dec 21 | 27 | 0 | 29 | 24 |
| 30 Sep 21 | 7 | -24 | 24 | 18 |
| 30 Jun 21 | 18 | -118 | 20 | 0 |
| 31 Mar 21 | 16 | -119 | 16 | 0 |
| 31 Dec 20 | 11 | -23 | 14 | 29 |
| 30 Sep 20 | 11 | -41 | 14 | 0 |
| 30 Jun 20 | 0 | -32 | 13 | 0 |
| 31 Mar 20 | 0 | -60 | 13 | 0 |
| 31 Dec 19 | 0 | -107 | 12 | 0 |
| 30 Sep 19 | 0 | -81 | 12 | 0 |
| 30 Jun 19 | 0 | -82 | 13 | 0 |
| 31 Mar 19 | 0 | -36 | 13 | 0 |
| 31 Dec 18 | 0 | -34 | 12 | 0 |
| 30 Sep 18 | 0 | -33 | 10 | 0 |
| 30 Jun 18 | 0 | -29 | 8 | 0 |
| 31 Mar 18 | 0 | -27 | 8 | 0 |
| 31 Dec 17 | 0 | -29 | 8 | 0 |
| 30 Sep 17 | 1 | -26 | 6 | 0 |
| 30 Jun 17 | 30 | 3 | 10 | 0 |
| 31 Mar 17 | 30 | 3 | 12 | 0 |
| 31 Dec 16 | 30 | 2 | 11 | 0 |
| 30 Sep 16 | 30 | -5 | 14 | 0 |
| 30 Jun 16 | 1 | -34 | 11 | 0 |
| 31 Mar 16 | 1 | -35 | 9 | 0 |
Quality Earnings: PCBK is currently unprofitable.
Growing Profit Margin: PCBK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCBK is unprofitable, but has reduced losses over the past 5 years at a rate of 18.7% per year.
Accelerating Growth: Unable to compare PCBK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCBK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.9%).
Return on Equity
High ROE: PCBK has a negative Return on Equity (-12.57%), as it is currently unprofitable.